How to Transition from Duloxetine (Cymbalta) to Atomoxetine (Strattera)
Taper duloxetine slowly over several weeks to avoid discontinuation syndrome, then initiate atomoxetine at a low starting dose with gradual titration once duloxetine is discontinued.
Discontinuing Duloxetine
Duloxetine requires a slow taper to minimize discontinuation syndrome, which can include dizziness, fatigue, nausea, headaches, sensory disturbances, and irritability 1. The SNRI class, including duloxetine, has been associated with discontinuation symptoms following missed doses or abrupt cessation 1.
Tapering Strategy:
- Reduce the dose gradually over 2-4 weeks minimum, using the smallest available dose decrements
- Avoid alternate-day dosing, as this creates significant fluctuations in drug levels and receptor occupancy, substantially increasing withdrawal risk 2
- Use daily dosing throughout the taper to maintain stable plasma levels
- A slower titration with lower starting doses improves tolerability 3
Critical Pitfall: Do not switch to every-other-day dosing when tapering duloxetine. Research demonstrates this approach causes pronounced receptor occupancy variation and likely triggers withdrawal symptoms 2.
Initiating Atomoxetine
According to FDA labeling, atomoxetine can be discontinued without tapering and does not require a washout period 4. However, complete the duloxetine taper before starting atomoxetine to avoid overlapping serotonergic effects and to clearly distinguish which medication is causing any adverse effects.
Atomoxetine Starting Protocol:
For children/adolescents ≤70 kg:
- Start at 0.5 mg/kg/day
- Increase after minimum 3 days to target dose of 1.2 mg/kg/day
- Maximum dose: 1.4 mg/kg or 100 mg daily, whichever is less 4
For children/adolescents >70 kg and adults:
- Start at 40 mg/day
- Increase after minimum 3 days to target of 80 mg/day
- May increase to 100 mg after 2-4 additional weeks if needed
- Maximum dose: 100 mg daily 4
Optimizing Tolerability:
- Use divided dosing (morning and late afternoon/evening) during initial titration to minimize adverse effects like nausea, somnolence, and abdominal discomfort 5
- Slow titration reduces adverse event onset: Fast titration significantly shortens time to onset of abdominal pain, decreased appetite, and somnolence 5
- Consider a trial period of 6-8 weeks before evaluating overall efficacy 6
- Atomoxetine may be taken with or without food 4
Monitoring During Transition
- Cardiovascular parameters: Monitor heart rate and blood pressure at baseline and during titration, as atomoxetine can increase both 7
- Hepatic function: Obtain baseline liver function if risk factors present (duloxetine has been associated with hepatic failure) 1
- Psychiatric symptoms: Monitor for suicidal ideation (FDA black box warning for atomoxetine) 7
- Growth parameters: Track height and weight in pediatric patients 7
Special Considerations
CYP2D6 interactions: If the patient was taking duloxetine with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine), or if the patient is a known CYP2D6 poor metabolizer, maintain atomoxetine at the lower starting dose (0.5 mg/kg or 40 mg) for 4 weeks before increasing 4.
Previous stimulant use: Approximately 50% of methylphenidate non-responders will respond to atomoxetine, and about 75% of methylphenidate responders will also respond to atomoxetine 6. Patients switching from stimulants to atomoxetine can successfully transition with cross-tapering 8, though this is not relevant for your duloxetine-to-atomoxetine switch.
Key advantage: Unlike duloxetine, atomoxetine can be discontinued abruptly without rebound effects or discontinuation syndrome if needed 6.